奥泰生物
(688606)
| 流通市值：34.59亿 | | | 总市值：34.59亿 |
| 流通股本：7565.44万 | | | 总股本：7565.44万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 392,144,917.68 | 195,372,450.28 | 905,344,393.81 | 633,076,568.3 |
| 营业收入 | 392,144,917.68 | 195,372,450.28 | 905,344,393.81 | 633,076,568.3 |
| 二、营业总成本 | 345,033,080.78 | 178,180,947.39 | 711,573,116.92 | 457,636,927.5 |
| 营业成本 | 183,954,455.35 | 91,989,354.41 | 444,092,851.5 | 277,209,577.75 |
| 税金及附加 | 10,691,496.37 | 6,092,176.39 | 9,545,644.5 | 4,379,227.65 |
| 销售费用 | 30,564,898.56 | 16,791,367.7 | 79,315,434.57 | 59,896,478.03 |
| 管理费用 | 39,777,220.08 | 19,679,078.01 | 79,749,015.03 | 54,308,035.1 |
| 研发费用 | 60,384,755.92 | 28,746,985.17 | 109,316,439.07 | 74,216,918.14 |
| 财务费用 | 19,660,254.5 | 14,881,985.71 | -10,446,267.75 | -12,373,309.17 |
| 其中:利息费用 | 158,237.55 | 206,798.03 | 280,377.88 | 224,732.93 |
| 其中:利息收入 | 13,474,004.03 | 4,475,913.87 | 25,494,862.47 | 18,003,219.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 13,345,598.16 | 5,618,393.47 | 40,611,636.15 | 18,960,527.98 |
| 加:投资收益 | -5,519,581.89 | 726,239.24 | 335,646.32 | 8,831,717.6 |
| 资产处置收益 | 65,174.37 | 65,044.06 | 616,679.63 | 616,679.63 |
| 资产减值损失(新) | -1,006,923.8 | -50,597.96 | -4,261,937.03 | -608,005.17 |
| 信用减值损失(新) | -2,735,269.54 | -3,319,223.51 | -3,176,624.43 | -7,250,968.48 |
| 其他收益 | 2,729,397.96 | 1,412,309.92 | 23,913,422.32 | 22,818,985.29 |
| 四、营业利润 | 53,990,232.16 | 21,643,668.11 | 251,810,099.85 | 218,808,577.65 |
| 加:营业外收入 | 169,603.53 | 172,124.11 | 452.66 | 277.3 |
| 减:营业外支出 | 136,938.94 | 55,869.09 | 633,883.47 | 562,891.71 |
| 五、利润总额 | 54,022,896.75 | 21,759,923.13 | 251,176,669.04 | 218,245,963.24 |
| 减:所得税费用 | 3,380,763.64 | 2,628,934.73 | 31,104,761.64 | 28,522,829.07 |
| 六、净利润 | 50,642,133.11 | 19,130,988.4 | 220,071,907.4 | 189,723,134.17 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 50,642,133.11 | 19,130,988.4 | 220,071,907.4 | 189,723,134.17 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 50,844,708.31 | 19,394,345.33 | 220,191,901.65 | 189,809,703.81 |
| 少数股东损益 | -202,575.2 | -263,356.93 | -119,994.25 | -86,569.64 |
| 扣除非经常损益后的净利润 | 41,772,372.81 | 11,772,864.62 | 157,141,091.91 | 147,068,606.58 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.64 | 0.24 | 2.78 | 2.39 |
| (二)稀释每股收益 | 0.64 | 0.24 | 2.78 | 2.39 |
| 八、其他综合收益 | 361,784.48 | 308,042.58 | -361,475.92 | -608,935.67 |
| 归属于母公司股东的其他综合收益 | 387,157.6 | 301,101.44 | -330,302.5 | -610,326.63 |
| 九、综合收益总额 | 51,003,917.59 | 19,439,030.98 | 219,710,431.48 | 189,114,198.5 |
| 归属于母公司股东的综合收益总额 | 51,231,865.91 | 19,695,446.77 | 219,861,599.15 | 189,199,377.18 |
| 归属于少数股东的综合收益总额 | -227,948.32 | -256,415.79 | -151,167.67 | -85,178.68 |
| 公告日期 | 2026-08-29 | 2026-04-20 | 2026-04-20 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |